ArticleBMC medical imaging2026
Microstructural MRI combined with metabolic MRI to evaluate the progression-free survival of patients with glioblastoma at the early follow-up after tumor treating fields: a pilot study.
Article in BMC medical imaging, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundNon-invasive assessment of treatment response in Tumor Treating Fields (TTFields) and exploration of progression-free survival (PFS) by imaging techniques remains a major challenge.
objectivesThis exploratory pilot study investigated the feasibility of using time-dependent diffusion MRI (t
methodsThis study employed t
resultsTen patients were included (age range 29-74 years; 8 men). The TTFields group showed a trend toward greater early reduction in cellularity index at first follow‑up. LMM analysis showed different dynamic evolution trends in Diameter (F = 5.042, P = 0.035) and pH-weighted values (F = 5.291, P = 0.055) between the progression and non-progression groups. At the third month post-treatment, the Diameter in the progression group increased from baseline, while it decreased in the non-progression group (estimated value = 3.17, 95% CI: 0.29-6.06, P = 0.036). Sensitivity analyses supported these descriptive between‑group differences. Correlation analysis showed that at the third month post-treatment, the change in diameter was associated with the pH-weighted change (r = 0.697, P = 0.025). During the early treatment phase, both the change in diameter and the pH-weighted change relative to baseline showed negative associations with patient PFS (r = -0.636, P = 0.048; r = -0.697, P = 0.025).
conclusionsThis exploratory pilot study suggested that combining t CRITICAL RELEVANCE STATEMENT: Early assessment of the efficacy of TTFields for GBM is key to individualized therapy, but challenges remain. This exploratory pilot study combined microstructural and metabolic MRI to describe early longitudinal changes linked to TTFields response. The preliminary findings provided initial insights that may inform future larger-scale studies aimed at better understanding treatment response in GBM patients. CLINICAL TRIAL NUMBER: Not applicable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.